Why CAMP4?
Leadership
About Our Name
RAP Platform
RNA Actuators
Programmable Therapeutics
Publications & Presentations
Pipeline
Investors
Newsroom
Join the Adventure
Recent News
October 11, 2024
Camp4 CEO credits CFO, investors’ ‘risk appetite’ for IPO
Read More
Contact Us
Privacy Policy
Terms of Use
Menu
Newsroom
Views and missives from the frontier
All
Perspectives
In the News
Videos
October 11, 2024
In the News
BBJ
Camp4 CEO credits CFO, investors’ ‘risk appetite’ for IPO
October 11, 2024
In the News
Endpoints
Biotech startups Upstream and CAMP4 price Friday IPOs
October 1, 2024
In the News
Fierce Biotech
CAMP4, BioMarin ink research deal for genetic disease targets
April 17, 2024
In the News
Drug Discovery World
Turning science into business: Amplifying mRNA by targeting regRNAs
April 26, 2023
In the News
Popular Science
New therapies offer hope for patients with rare genetic conditions
August 3, 2022
In the News
GEN Edge
Mountain Climbing: CAMP4 Aims to Scale the Heights of Disease
July 28, 2022
In the News
Business Insider
Meet the 23 Biotech Startups that are set to take off in the next 12 months, according to VCs
July 20, 2022
In the News
Boston Globe
Cambridge startup CAMP4 Therapeutics raises $100 million for RNA therapies
1
2
3
»
Media Contact:
PR@camp4tx.com
Top